Schubert & CO Exelixis, Inc. Transaction History

Schubert & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	BUY	$16.3 - $19.41 $668 - $795	41 Added 58.57%	111 $2,000
Q4 2022 Jan 31, 2023	BUY	$14.96 - $17.39 $89 - $104	6 Added 9.38%	70 $1,000
Q3 2022 Oct 21, 2022	SELL	$15.68 - $22.27 $501 - $712	-32 Reduced 33.33%	64 $1,000
Q2 2022 Aug 01, 2022	BUY	$17.44 - $23.16 $819 - $1,088	47 Added 95.92%	96 $2,000
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $408 - $544	24 Added 96.0%	49 $1,000
Q4 2021 Jan 28, 2022	BUY	$15.84 - $21.88 $396 - $547	25 New	25 $0

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

Stay updated on Schubert & CO with notifications on news.